Investing in Johnson & Johnson

Johnson & Johnson has been a part of people's lives for more than 120 years and a valuable part of their investments for more than 60 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses in the world, generating more than 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.

Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 75 consecutive years of sales increases; 24 consecutive years of adjusted earnings increases; and 46 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 9.1 percent total return for investors compared to a 5.9 percent total return for the S&P 500.

Our consumer products, pharmaceuticals, medical devices and diagnostics play a role in helping millions of people be well and stay well every day. We remain committed to improving the health and well-being of people everywhere, profitably growing our businesses, and enhancing the value we can bring to our shareholders.

Investor News

August 5, 2008
Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008

August 1, 2008
Veridex Completes Acquisition of Immunicon Corporation Assets

July 30, 2008
Johnson & Johnson (China) Investment Co., Ltd. Acquires Beijing Dabao Cosmetics Co., Ltd.

Investor Communications

July 15, 2008 at 8:30 AM ET
Johnson & Johnson Second Quarter 2008 Earnings Conference Call

Financial Quick Links

2007 Annual Report

Q2 2008 Earnings Announcement

Q2 2008 Sales of Key Products/Franchises

Investor Facts

5 Year Financial Review